Preclinical therapeutic targets in diffuse midline glioma

Michaël Hananja Meel, Gertjan J. L. Kaspers, Esther Hulleman

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)


Diffuse midline gliomas (DMG) are rapidly fatal tumors of the midbrain in children, characterized by a diffuse growing pattern and high levels of intrinsic resistance to therapy. The location of these tumors, residing behind the blood-brain barrier (BBB), and the limited knowledge about the biology of these tumors, has hindered the development of effective treatment strategies. However, the introduction of diagnostic biopsies and the implementation of autopsy protocols in several large centers world-wide has allowed for a detailed characterization of these rare tumors. This has resulted in the identification of novel therapeutic targets, as well as major advances in understanding the biology of DMG in relation to therapy resistance. We here provide an overview of the cellular pathways and tumor-specific aberrations that have been targeted in preclinical DMG research, and discuss the advantages and limitations of these therapeutic strategies in relation to therapy resistance and BBB-penetration. Therewith, we aim to provide researchers with a framework for successful preclinical therapy development.
Original languageEnglish
Pages (from-to)15-25
JournalDrug resistance updates
Publication statusPublished - 1 May 2019

Cite this